Afamelanotide Assists DNA Repair Response Following UVR
Filed with ASX · · 3 pages · English
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings CallClinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- CLINUVEL extends Managing Director Employment Agreement
- afamelanotide in fair-skinned Parkinsons patients
- CLINUVEL initiates on market share buy-back program
- New case of SCENESSE efficacy in vitiligo presented at AAD
- SCENESSE provides photoprotection in variegate porphyria
Later from Clinuvel Pharmaceuticals
- Vitiligo and Operational Update
- Appendix 4E and Annual Report to Shareholders 2024
- CLINUVEL delivers increases in annual revenue, profit
- Canadian New Drug Submission for SCENESSE in EPP filed
- Managing Director Presentation
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals